Revenue: As of FY2025, the actual value is USD 0.

The provided Form 8-K filing by Immunic, Inc. does not include core financial results such as segment revenue, gross margin, operating profit, or cash flow, as these were announced separately . However, it details certain financial commitments and operational expenses.

Operational Expenses

• Total Operating Expenses: For the three months ended June 30, 2026, total operating expenses were $35.3 million, compared to $27.1 million for the same period in 2025 . For the six months ended June 30, 2026, these expenses were $68.6 million, an increase from $53.9 million in 2025 . These figures include non-cash charges, primarily stock compensation expense, of $7.2 million for the three months and $11.7 million for the six months ended June 30, 2026 .
• Research and Development (R&D) Expenses: R&D expenses reached $25.9 million for the three months ended June 30, 2026, up from $21.3 million in 2025 . For the six months ended June 30, 2026, R&D expenses were $51.6 million, an increase from $42.9 million in 2025 . The increases were mainly due to higher personnel expenses, drug-drug interaction studies, and vidofludimus calcium drug supply .
• General and Administrative (G&A) Expenses: G&A expenses were $9.4 million for the three months ended June 30, 2026, an increase from $5.7 million in 2025 . For the six months ended June 30, 2026, G&A expenses totaled $17.0 million, up from $11.0 million in 2025 . This rise was primarily driven by increased personnel expenses, legal and consultancy fees, and pre-commercial marketing expenses .

Other Income and Loss

• Interest Income: Interest income increased to $1.3 million for the three months ended June 30, 2026, from $0.3 million in 2025, and to $2.0 million for the six months ended June 30, 2026, from $0.4 million in 2025, due to a higher average cash balance .
• Other Income (Expense): Other income (expense) was - $0.06 million for the three months ended June 30, 2026, compared to $0.02 million in 2025 . For the six months ended June 30, 2026, it was - $0.2 million, a decrease from $1.2 million in 2025, primarily due to the absence of a $1.0 million grant income recognized in Q1 2025 .
• Net Loss: The net loss for the three months ended June 30, 2026, was approximately - $34.1 million, compared to approximately - $26.8 million for the same period in 2025 . For the six months ended June 30, 2026, the net loss was approximately - $66.7 million, compared to approximately - $52.3 million for the same period in 2025 .

Cash Position

• Cash and Cash Equivalents: As of June 30, 2026, Immunic, Inc. reported $155.1 million in cash and cash equivalents, significantly up from $15.5 million as of December 31, 2025 . The company anticipates these funds will support operations into late 2027 .

Director Compensation

• Equity Grant: Elena Ridloff received an inaugural grant of options to purchase up to 50,740 shares of Immunic, Inc.’s common stock, vesting monthly over three years, upon her appointment as a director .
• Cash Compensation: Ms. Ridloff will also receive cash compensation for her Board service in line with Immunic, Inc.’s non-employee director compensation policy .

Executive Separation Agreement (Dr. Daniel Vitt)

• Consulting Retainer: Dr. Vitt will receive a monthly retainer of €15,000 for up to 15 hours of consulting services per month for an initial 12-month period .
• Severance Salary Payment: Immunic, Inc. and its subsidiary agreed to pay Dr. Vitt his base salary for 16.5 months following the Separation Date . The first 12 installments, totaling $670,000, will be paid in a lump sum, with the remaining 4.5 months paid in five monthly installments, the last at half pay .
• Bonus Payment: A lump sum bonus payment of $276,375 (or Euro equivalent), representing 75% of his target bonus for fiscal year 2026, will be paid .
• Healthcare Reimbursement: Immunic, Inc.’s subsidiary will reimburse Dr. Vitt for monthly healthcare costs in Germany, up to €1,500 per month, for 18 months .
• Equity Vesting: 100% of Dr. Vitt’s outstanding equity awards vested as of the Separation Date, with a three-year window to exercise them .
• Legal Fees Reimbursement: Immunic, Inc. will reimburse Dr. Vitt for legal fees incurred in negotiating the Separation Agreement, up to a maximum of $20,000 .

Outlook / Guidance

Immunic, Inc. expects top-line data from its Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis by year-end 2026 . The company plans to initiate a confirmatory Phase 3 program in progressive multiple sclerosis later in 2026 . If the data is positive, a New Drug Application (NDA) submission in the United States is targeted for mid-2027, with potential regulatory approval in 2028 .